Figueroa RG, Álvarez RV, Gudiño SEF

Language: Spanish
References: 23
Page: 101-107
PDF size: 237.72 Kb.

ABSTRACT

Multiple myeloma (MM) is a malignant disease of plasma cells of B lymphocytes. Bluefarb estimated that approximately 15% of MM patients will develop some form of amyloidosis. The term amyloidosis refers to the extracellular accumulation of an amyloid material, due to a poor folding of autological proteins. The lambda light chain amyloidosis subtype is the most common in MM-associated cutaneous amyloidosis. In Mexico, the frequency of cutaneous amyloidosis in the dermatological consultation is only 0.5% and predominantly in women. Tissue infiltration by these amyloid residues occurs either locally or systemically. When amyloidosis affects the skin, it can be as a manifestation of systemic amyloidosis, or localized cutaneous amyloidosis. Cutaneous amyloid diseases can have heterogeneous manifestations, specific to the location of the amyloid deposit within the dermis or epidermis. The diagnosis of amyloidosis is made histologically by demonstrating the amyloid deposit. The treatment of amyloidosis is focused on each type. Patients with AL amyloidosis-associated myeloma with skin involvement have the worst prognosis.

REFERENCES

1. Bergstrom DJ, Kotb R, Louzada ML, Sutherland HJ, Tavoularis S, Venner CP; Myeloma Canada Research Network Consensus Guideline Consortium. Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma canada research network consensus guideline consortium. Clin Lymphoma Myeloma Leuk. 2020; 20 (7): e352-e367. doi: 10.1016/j.clml.2020.01.017.

2. Kois JM, Sexton FM, Lookingbill DP. Cutaneous manifestations of multiple myeloma. Arch Dermatol. 1991; 127 (1): 69-74. doi: 10.1001/archderm.1991.01680010079012.

3. López L, González K, Navarrete G, Novales J, Guarneros A, Cortés B et al. Multiple myeloma and systemic amyloidosis. Int J Dermatol. 2008; 47 (2): 165-167. doi: 10.1111/j.1365-4632.2008.03352.x.

4. Chuang YY, Lee DD, Lin CS, Chang YJ, Tanaka M, Chang YT et al. Characteristic dermoscopic features of primary cutaneous amyloidosis: a study of 35 cases. Br J Dermatol. 2012; 167 (3): 548-554. doi: 10.1111/j.1365-2133.2012.11066.x.

5. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento. 6a edición. Ciudad de México: McGraw Hill Education; 2015.

6. Cohen OC, Wechalekar AD. Systemic amyloidosis: moving into the spotlight. Leukemia. 2020; 34 (5): 1215-1228. doi: 10.1038/s41375-020-0802-4.

7. Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ et al. Fitzpatrick's dermatology. 9th edition. Nueva York: McGraw Hill Education; 2019.

8. Lavorato FG, Alves Mde F, Maceira JM, Unterstell N, Serpa LA, Azulay-Abulafia L. Primary systemic amyloidosis, acquired cutis laxa and cutaneous mucinosis in a patient with multiple myeloma. An Bras Dermatol. 2013; 88 (6 Suppl 1): 32-35. doi: 10.1590/abd1806-4841.20132531.

9. Medina-Castillo DE, Quiroz-Mejía R, Caliope-Carrera E, Paredes-Ceballos O, Aranda-Díaz EI, Barrios-González JA et al. Amiloidosis sistémica. Dermatol Rev Mex. 2015; 59: 208-218.

10. Oliveira EV, Pozetti AC, Pozetti EM, Antonio JR, Michalany NS. Primary systemic amyloidosis associated with multiple myeloma. An Bras Dermatol. 2012; 87 (1): 119-122.

11. Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood. 2012; 120 (16): 3206-3213. doi: 10.1182/blood-2012-03-413682.

12. Rubinow A, Cohen AS. Skin involvement in generalized amyloidosis. A study of clinically involved and uninvolved skin in 50 patients with primary and secondary amyloidosis. Ann Intern Med. 1978; 88 (6): 781-785. doi: 10.7326/0003-4819-88-6-781.

13. Saúl A. Saúl. Lecciones de dermatología. 16a edición. Ciudad de México: McGraw Hill Education; 2015.

14. Caruana D, McCusker S, Harper C, Bilsland D. Curious facial plaque diagnosed as nodular primary localised cutaneous amyloidosis. BMJ Case Rep. 2019; 12 (5): e228163. doi: 10.1136/bcr-2018-228163.

15. Andrei M, Wang JC. Cutaneous light chain amyloidosis with multiple myeloma: a concise review. Hematol Oncol Stem Cell Ther. 2019; 12 (2): 71-81. doi: 10.1016/j.hemonc.2018.09.003.

16. Moatamedi M, Derakhshan MH. Images of the month 4: cutaneous amyloidosis: a clinical challenge. Clin Med (Lond). 2019; 19 (5): 418-420. doi: 10.7861/clinmed.2019-0221.

17. Dupont L, Martins Souza PR, Damiani L, Boff AL. Cutaneous nodular amyloidosis: a disfiguring aspect of the face. Am J Dermatopathol. 2019; 41 (12): 945-947. doi: 10.1097/DAD.0000000000001470.

18. Kaliyadan F, Alkhateeb A, Kuruvilla J, Swaroop K, Alabdulsalam AA. Dermoscopy of primary cutaneous amyloidosis in skin of color. Dermatol Pract Concept. 2019; 9 (3): 232-234. doi: 10.5826/dpc.0903a17.

19. Weidner T, Illing T, Elsner P. Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol. 2017; 18 (5): 629-642. doi: 10.1007/s40257-017-0278-9.

20. Penner CR, Muller S. Head and neck amyloidosis: a clinicopathologic study of 15 cases. Oral Oncol. 2006; 42 (4): 421-429. doi: 10.1016/j.oraloncology.2005.09.010.

21. Rysavá R. AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 2019; 34 (9): 1460-1466. doi: 10.1093/ndt/gfy291.

22. Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012; 119 (19): 4387-4390. doi: 10.1182/blood-2011-10-388462.

23. Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017; 130 (7): 900-902. doi: 10.1182/blood-2017-01-763599.